Stacey Chang-Douglass
Head of Health Economics and Director in Consulting
Stacey is Head of Health Economics and Director in Consulting at Clarivate.
Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.
Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.
Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.
Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.
Latest news
Clarivate Expands Access to Trusted Regulatory Intelligence Within Claude
Advancing Clarivate strategy to extend proprietary intelligence into enterprise AI ecosystems Bringing Clarivate domain-specific regulatory insights into Claude to support life sciences workflows LONDON, U.K, March 10, 2026 Clarivate Plc…
National Research Council of Italy Joins Early Adopter Cohort for Web of Science Research Intelligence
London, U.K. March 9, 2026: Consiglio Nazionale delle Ricerche (CNR), the National Research Council of Italy, has joined the early adopter program for Web of Science Research Intelligence from Clarivate,…
Clarivate Library Innovation Awards Reveal the 2026 Finalists
An independent judging panel selected finalists who demonstrated exceptional creativity, innovation and impact London, U.K. March 5, 2026. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced…
